Oct 15 2026 09:23 PM EST
Gossamer Bio Shares Slide as Phase‑III Miss and Funding Concerns Emerge
Gossamer Bio (NASDAQ:GOSS) fell sharply after the Phase III PROSERA trial missed its primary endpoint in February 2026 and the company disclosed a cash balance of only $57 million at the end of June 2026, prompting investors to reassess its financing strategy and near‑term runway.
The miss triggered an immediate 77‑80% drop in GOSS shares, and the stock has since lost 75.3% over the past six months and 95.4% over the last year. Recent five‑day performance is down 9.9% and three‑month performance is down 31.3%.
Phase‑III Endpoint Miss Undermines Clinical Outlook
The PROSERA study, a registrational Phase III trial of seralutinib in pulmonary arterial hypertension (PAH), missed the prespecified statistical threshold for its primary endpoint. Gossamer said the totality of evidence still supports activity, but the miss led the company to pause enrollment in the parallel SERANATA PH‑ILD study while it evaluates the data. The market reaction was swift, with the share price falling roughly 80% on the news.
Cash Burn Accelerates and Funding Plan Becomes Central
Cash balances fell from $180 million at September 2025 to $99.2 million at March 2026, and further to $57 million by June 2026. The company’s free‑cash‑flow‑to‑sales ratio for the trailing twelve months ending Q2 2026 is a negative 305.2%, reflecting a cash‑burn rate of roughly $170.3 million over the twelve months to March 2026.
To bridge the gap to a potential FDA decision, Gossamer announced a structured private placement of up to $250 million. The initial tranche of about $25 million is expected to close in late August 2026, with a second tranche of roughly $125 million contingent on FDA acceptance of the seralutinib NDA, and up to an additional $100 million upon approval. While the financing extends the cash runway into 2028, it is highly dilution‑linked and dependent on regulatory milestones that have already proven uncertain.
Revenue Decline and Operating Losses
Revenue fell to $9.24 million in Q2 2026, a year‑over‑year decline, though it beat the consensus estimate of $5.30 million (+74.4% surprise). R&D expenses contracted to $26.4 million in the same quarter. The company reported a net loss of $46.7 million in Q1 2026 and a FY 2025 net loss of $170.4 million, reflecting operating margins of -297.7% for the trailing twelve months ending Q2 2026.
Regulatory Timeline and Market Valuation
Gossamer plans to submit an NDA for seralutinib in PAH in September 2026, with FDA acceptance required for the second financing tranche. A decision on the NDA could arrive as early as Q3 2027. The market has priced the stock at roughly $0.15 after an intraday surge to $0.21 on financing news (a >31% jump) and a subsequent close down 5.59%.
Analyst coverage is fragmented. Median price target is $1.00, average target $3.20, with a consensus range of $0.28‑$4.00. Chardan Capital maintains a Buy rating with a $160 target, an outlier relative to the broader consensus. The GF Score of 24/100 underscores weak financial strength and limited momentum.
Risks and Outlook
Key risks include the possibility that the FDA does not accept the NDA, which would block the $125 million tranche and force the company to seek alternative financing while cash continues to decline. Additional dilution could arise from warrant exercises if the contingent milestones are met. The Phase III miss also casts uncertainty on the commercial potential of seralutinib in both PAH and PH‑ILD. A continued cash burn without near‑term revenue growth could pressure the stock further.
Investors will be watching the September 2026 NDA filing, the outcome of the FDA review, and any updates on the SERANATA study. Until those milestones are clarified, the stock’s steep decline reflects a market that remains skeptical about Gossamer’s ability to translate its clinical program into sustainable cash flow.